Weekly paclitaxel in advanced non-small cell lung cancer

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 14, 2001, Pages 10-13

  Alex Yuang Chi Chang, ^a,c   Rubins, Jonathan ^a,b   Asbury, Robert ^a,b   Boros, Laszlo ^a,b   Lai Fong Hui, ^a,b  

^a Johns Hopkins Singapore   (Singapore)

^b Interlakes Oncology and Hematology PC   (United States)

^c NATIONAL UNIVERSITY HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFECTION; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 0034786856     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.27607     Document Type: Article

References (25)

1. Chemotherapy vs supportive care in advanced non-small-cell lung cancer: Results of a meta-analysis of the literature
2. Survival determinants in extensive-stage non-small-cell lung cancer. The Southwest Oncology Group experience
3. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: Results of an Eastern Cooperative Oncology Group trial
4. A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer
5. Promotion of microtubule assembly in vitro by Taxol
6. The microtubule-affecting drug paclitaxel has antiangiogenic activity
7. Mitotic block induced in HeLa cells by low concentration of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death
8. Taxolinduced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway
9. Mechanisms of Taxol-induced cell death are concentration dependent
10. Paclitaxel as a radiation sensitizer in non-small cell lung cancer
11. One-hour paclitaxel plus carhoplatin in the treatment of advanced non-small cell lung cancer: Results of a multicenter phase II trial
12. Taxol: A novel investigational antimicrotubule agent
13. Taxol-based combination chemotherapy and other in vivo preclinical antitumor studies
14. Taxol in the treatment of non-small cell lung cancer
15. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients: With locally advanced or metastatic non-small-cell lung cancer
16. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans
17. Weekly paclitaxel with and without concurrent radiation therapy: Toxicity, pharmacokinetics, and response
18. Second-line weekly paclitaxel in patients with advanced non-small cell lung cancer failing first line carboplatin/paclitaxel
19. Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents
20. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
21. Weekly paclitaxel in patients with advanced lung cancer: Preliminary data from a phase II trial
22. CALGB 9731: Phase II trial of weekly paclitaxel for advanced non-small cell lung cancer
23. Dose-dense therapy with weekly 1-hour paclitaxel infusion in the treatment of metastatic breast cancer
24. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer
25. Beta-tubulin mutations in circulating extracellular DNA of non-small cell lung cancer patients